|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 11, 2021 )
Market Overview
Allogeneic stem cell transplant uses healthy blood stem cells from a donor to replace diseased or damaged bone marrow.
View full report: https://bit.ly/3BuPebv
Market Dynamics
The increasing prevalence of Ischemic heart disease is expected to drive the market's growth.
According to the National Center for Biotechnology Information, Ischemic heart disease, also called coronary heart disease (CHD), is a heart problem caused by narrowed heart (coronary) arteries that supply blood to the heart muscle.
Although the narrowing is caused by a blood clot or by constriction of the blood vessel, it is often caused by the buildup of plaque, called atherosclerosis. IHD affects around 126 million individuals (1,655 per 100,000), approximately 1.72% of the world's population.
Moreover, nine million deaths were caused by IHD globally. Men were more usually affected than women, and incidence typically started in the fourth decade and increased with age.
The study estimated that the current prevalence rate of 1,655 per 100,000 population is expected to exceed 1,845 by 2030. Stem cell transplantation has become a viable approach for the treatment of IHD in recent times.
Additionally, it is generally recognized that preclinical cell-based therapy is effective and has yielded encouraging results, which involves preventing or reducing myocardial cell death, inhibiting scar formation, promoting angiogenesis, and improving cardiac function. Thus, the allogeneic stem cells market is expected to propel in the forecast period from the above statements.
Market Segment Analysis
By Product
• Progesterone Oral
• Progesterone Injection
• Progesterone Suspended/Gel
By Application
• Hospital
• Clinic
• Pharmacies and Drug Stores
Download free sample: https://bit.ly/2X0AulL
Geographical Analysis
North America region holds the largest market share in the global allogeneic stem cells market.
North America dominated the market in 2020. The region's growth is attributed to the increase in economic growth and the increase in the prevalence of target chronic diseases, rise in the investment scenario, high adoption of advanced technology is expected to boost the market in the forecast period.
For instance, according to BioMed Central, published on 25 November 2020, allogeneic hematopoietic stem cell transplantation after CAR T-cell therapy has appeared as a promising strategy to prolong leukemia-free survival (LFS).
Although anti-CD19 chimeric antigen receptor (CAR) T-cell therapy shows much effectiveness in patients with relapsed/ refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), it fails to develop long-term leukemia-free survival (LFS).
Moreover, recent clinical data show that patients with complex karyotypes, adverse genes, and high pre-infusion minimal residual disease (MRD) by flow cytometry in the bone marrow had a high chance of relapse after CAR T-cell therapy.
But patients having these risk factors, consolidative allo-HSCT after CAR T-cell therapy may prolong LFS. However, advances in chimeric antigen receptor (CAR) T-cell therapy have enhanced the treatment of r/r B-ALL, as the first FDA-approved CD19-targeted CAR T-cell therapy, Tisagenlecleucel, has recently been proved as the standard of care for r/r B-ALL patients aged under 26 as per the NCCN Guidelines. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Competitive Landscape
The allogeneic stem cells market is vast with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Biosolution Co. Ltd., Cynata Therapeutics Ltd., JCR Pharmaceuticals Co. Ltd., Lineage Cell Therapeutics Inc., MEDIPOST Co. Ltd., MiMedx Group Inc., Osiris Therapeutics Inc., Stempeutics Research Pvt. Ltd., and Takeda Pharmaceutical Co. Ltd.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the allogeneic stem cells market globally.
Related Topic's
Cancer Stem Cells Market, Stem Cell Therapy for Diabetes and Related Conditions Market, Cancer Stem Cell Therapy Market, Induced Pluripotent Stem Cell Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
